EXPRESS: Response Rates at Week 10

0.0

25.6

0

20

40

60

80

100

Placebo(n=77)

Infliximab 5 mg/kg(n=301)

Per

cen

t of p

atie

nts

Per cent of patients withPASI Score of 0 (Clear)

0.0

39.0

Placebo(n=77)

Infliximab 5 mg/kg(n=292)

Per cent of patients withPhysician’s Global Assessment

of Cleared

1.3

47.1

Placebo(n=77)

Infliximab 5 mg/kg(n=291)

Per cent of patients withDLQI of 0

Adapted from presentations during Dermatology Update 2006

EXPRESS: Phase III

*P<0.001 vs. placebo

0

20

40

60

80

100

Placebo (n=77) Infliximab 5 mg/kg (n=301)

Per

cen

t of p

atie

nts

with

75%

Impr

ovem

ent i

n P

AS

I

0 2 6 10 14 22 24

Weeks

*

* * * *80.4% 82.2%

Adapted from presentations during Dermatology Update 2006

Efficacy of Systemic Therapies in Psoriasis

21%27%

34%49%

80%

0%

20%

40%

60%

80%

100%

Alefacept i.m. 15 mg Efalizumab 1 mg/kg/wk

Etanercept 25 mg BIW Etanercept 50 mg BIW

Infliximab 5 mg/kg

83%71% 68%

60%50%

0%

20%

40%

60%

80%

100%

PUVA CyA UVB MTX FAE

Alefacept: Lebwohl et al. Arch Dermatol 2003Efalizumab: Gordon et al. JAMA 2003 Menter et al. Arch Dermatol 2005Etanercept: Leonardi et al. N Engl J Med 2003Infliximab: Reich et al. Lancet 2005

PUVA, UVB: Spuls et al. Br J Dermatol 1997CyA, MTX: Heydendael et al. N Engl J Med 2003FAE: Altmeyer et al. J Am Acad Dermatol 1994

PASI 75 or equivalent; induction therapy (10 to 16 weeks)

Adapted from presentations during Dermatology Update 2006

Treat active TB to resolution

New patient office visit

PPD test positiveand active TB

Initiate latent TB treatment

Initiate therapyInitiate therapy

Administer appropriate TB screening test(PPD skin test + CXR + family history)

Evaluate test results

Test negative

Initiate therapy

PPD test positiveand normal CXR

Arend SM et al. Neth J Med 2003;61(4):111-9

Algorithm for TB Testing: European-based Recommendations